Noxopharm appoints Dr Olivier Laczka CEO

Australian clinical-stage biotech company Noxopharm Limited has appointed Dr Olivier Laczka as its Chief Executive Officer. A longstanding member of the company’s leadership team, Laczka was formerly Chief Scientific Officer – Inflammation.

Laczka had been a driving force behind the strategic development of the company’s Sofra technology platform, which “is focused on developing a novel class of immunomodulators capable of improving RNA vaccines and therapeutics, as well as treating autoimmune diseases”.

“Dr Laczka has made a very significant contribution to the development of the Sofra program and is the ideal person to steer the next phase of our growth,” Noxopharm Chairman Fred Bart said.

“He has led our scientific team with genuine vision and energy while forming deep collaborative relationships with our external partners, and we have real confidence in his ability to deliver value for our shareholders.”

On his appointment, Laczka said: “I am honoured to have been entrusted by the Board in this new role, and will take responsibility for building the company in our shareholders’ best interests.

“We have a real opportunity to grow by seizing the opportunities that are opening up for us, and not hesitating to make the right decisions that will take us forward.”

Image: Supplied.